PERKINELMER INC 

$115.24
119
-$1.06-0.91% Monday 20:03

统计

当日最高
-
当日最低
-
52周高点
-
52周低点
-
成交量
-
平均成交量
-
市值
0
市盈率
41.45
股息率
0.24%
股息
0.28

即将到来

股息

0.24%股息率
Feb 26
$0.07
Nov 25
$0.07
Aug 25
$0.07
May 25
$0.07
Feb 25
$0.07
10年增长
30.2%
5年增长
69.52%
3年增长
不适用
1年增长
不适用

财报

4May预期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
0.83
1.03
1.24
1.44
预期EPS
0.8811089113200001
实际EPS
不适用

财务

9.81%利润率
有盈利
2019
2020
2021
2022
2023
2024
2.76B营收
270.39M净利润

分析师评级

$110.71平均目标价
最高预估为 123.00。
来自过去6个月内的 8 条评分。这不是投资建议。
买入
38%
持有
63%
卖出
0%

其他人也在关注

此列表基于在 Stock Events 上关注 PKI 的用户自选生成。这不是投资建议。

竞争对手

此列表为基于近期市场事件的分析。并非投资建议。

关于

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Show more...
首席执行官
Dr. Prahlad R. Singh Ph.D.
员工
16700
国家
US

上市

0 Comments

分享你的想法

FAQ

PERKINELMER INC 今天的股价是多少?
PKI 当前价格为 $115.24 USD,在过去 24 小时内下跌了 -0.91%。在图表上更密切关注 PERKINELMER INC 股票的表现。
PERKINELMER INC 的股票代码是什么?
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,PERKINELMER INC 的股票以代码 PKI 进行交易。
PERKINELMER INC 去年的营收是多少?
PERKINELMER INC 去年的营收为 2.76BUSD。
PERKINELMER INC 去年的净利润是多少?
PKI 去年的净收益为 270.39MUSD。
PERKINELMER INC 会发放股息吗?
是的,PKI 的股息每 每季度 发放一次。每股最新股息为 0.01 USD。截至今日,股息率(FWD)% 为 0.24%。
PERKINELMER INC 有多少名员工?
截至四月 02, 2026,公司共有16,700名员工。
PERKINELMER INC 属于哪个行业?
PERKINELMER INC从事于Health Care行业。
PERKINELMER INC 何时完成拆股?
PERKINELMER INC 上次拆股发生在 六月 04, 2001,比例为 2:1。
PERKINELMER INC 的总部在哪里?
PERKINELMER INC 的总部位于 US 的 Waltham。